Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Bettina Bommer"'
Autor:
Bithi Chatterjee, Alexandre Simonin, Daniel Snell, Tea Gunde, Christian Hess, Matthias Brock, Stefan Warmuth, Christopher Weinert, Niels Kirk, Dania Diem, Robin Heiz, Dana Mahler, Sandro Wagen, Julia Zeberer, David Urech, Fabio Spiga, Nicole Bassler, Nina Schumacher, Yasemin Yaman, Bettina Bommer, Giorgio Gambino, Noreen Giezendanner, Benjamin Kuettner, Naomi Flueckiger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/f9b5336813e349368b3395de03a3a514
Autor:
Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Flückiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Küttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to en
Externí odkaz:
https://doaj.org/article/2cef15a66dc442d1a31020e1730a9800
Autor:
Stefan Warmuth, Tea Gunde, Daniel Snell, Matthias Brock, Christopher Weinert, Alexandre Simonin, Christian Hess, Julia Tietz, Maria Johansson, Fabio Mario Spiga, Robin Heiz, Naomi Flückiger, Sandro Wagen, Julia Zeberer, Dania Diem, Dana Mahler, Belinda Wickihalder, Simone Muntwiler, Bithi Chatterjee, Benjamin Küttner, Bettina Bommer, Yasemin Yaman, Peter Lichtlen, David Urech
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Co-stimulatory 4–1BB receptors on tumor-infiltrating T cells are a compelling target for overcoming resistance to immune checkpoint inhibitors, but initial clinical studies of 4–1BB agonist mAbs were accompanied by liver toxicity. We sought to en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c65a392b42386048d75da1b31b47ae5
https://pubmed.ncbi.nlm.nih.gov/35844969
https://pubmed.ncbi.nlm.nih.gov/35844969
Autor:
Bithi Chatterjee, Christian Hess, Daniel Snell, Tea Gunde, Stefan Warmuth, Alexandre Simonin, Matthias Brock, Fabio Spiga, Maria Johansson, Christopher Weinert, Julia Tietz, Niels Kirk, Nicole Bassler, Dana Mahler, Dania Diem, Alessandra Carrella, Noreen Giezendanner, Alessandra Alberti, Giorgio Gambino, Belinda Wickihalder, Bettina Bommer, Simone Muntwiler, Yasemin Yaman, Naomi Flueckiger, Robin Heiz, Sandro Wagen, David Urech
Publikováno v:
Cancer Research. 82:2871-2871
CD3-based T cell engagers are highly potent therapeutic molecules which enable T cell-mediated cytotoxic activity toward cells expressing selected tumor-associated antigens. Alongside a highly potent anti-tumor activity, is the risk of on-target off-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c7a4c193bb3250337bc2d869247fe0e
https://doi.org/10.1158/1538-7445.am2022-2871
https://doi.org/10.1158/1538-7445.am2022-2871